Evolution, current status, and prospects of clinical research guidelines for new traditional Chinese medicine drugs in China.
10.19540/j.cnki.cjcmm.20250411.501
- Author:
Zhong-Qi YANG
1
Author Information
1. First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510405, China.
- Publication Type:English Abstract
- Keywords:
clinical research;
guideline;
new traditional Chinese medicine drug
- MeSH:
Humans;
Biomedical Research/trends*;
China;
Clinical Trials as Topic;
Drugs, Chinese Herbal/therapeutic use*;
Guidelines as Topic;
Medicine, Chinese Traditional/standards*
- From:
China Journal of Chinese Materia Medica
2025;50(13):3574-3578
- CountryChina
- Language:Chinese
-
Abstract:
The guidelines for clinical research on new drugs provide unified standards for drug developers, researchers, and regulatory authorities, playing a crucial role in new drug development. This article systematically reviews the evolution of guidelines for clinical research on new traditional Chinese medicine(TCM) drugs in China, with a focus on analyzing the current status of these guidelines and the problems that exist. It also provides interpretations of three important guidelines. The article points out that with the continuous emergence of new clinical trial design methods, development concepts, and tools, and under the background of the "three combinations" evidence evaluation system for new TCM drugs, it is imperative to revise existing guidelines, formulate new ones, and develop new tools for clinical efficacy evaluation. It is hoped that relevant departments will adopt an open attitude and work together to build a technical system of clinical research guidelines for new TCM drugs that aligns with the characteristics of TCM.
